Clinical trials: Lymphoma, Malignant
Marginal Zone Lymphoma
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission…
- Trial name
- LYMFOR (NCT06125028)
- Testing
- [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose
- Where
- 12 sites in Austria, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Pentixapharm AG
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Multiple Myeloma, Non-Hodgkin Lymphoma
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- NCT04136756
- Testing
- NKTR-255, NKTR-255 Q21, Rituximab
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design.
- Trial name
- NCT04836195
- Testing
- PCLX-001 - 20mg, PCLX-001 - 40mg, PCLX-001 - 70mg
- Where
- 4 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Pacylex Pharmaceuticals
B-cell Non Hodgkin Lymphoma
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT06392477
- Testing
- SAR448501
- Where
- 16 sites in Australia, Serbia and 3 more
- Volunteers
- 96 people
- Sponsor
- Sanofi
MZL
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be…
- Trial name
- NCT03797456
- Testing
- ICP-022
- Where
- 32 sites in China
- Volunteers
- 111 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Non Hodgkin's Lymphoma, Large B-cell Lymphoma
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT06285422
- Testing
- SC262
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sana Biotechnology
Lymphoma, Follicular
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints…
- Trial name
- NCT00315731
- Testing
- Follicular Lymphoma
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06479356
- Testing
- Relma-cel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Advanced Follicular Lymphoma
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in…
- Trial name
- NCT03817853
- Testing
- Obinutuzumab, Bendamustine, Cyclophosphamide
- Where
- 33 sites in United States, Brazil and 5 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignancies
Phase I/II Clinical Study of 1A46 Drug Substance
A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell…
- Trial name
- NCT05987605
- Testing
- 1A46 Drug Substance
- Where
- China
- Volunteers
- 4 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Recurrent and Refractory Diffuse Large B-cell Lymphoma
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
The main objective of this study is to evaluate the differences in objective response rate and overall survival between the Purinostat mesylate for injection and selinexor, as assessed by blinded independent central review…
- Trial name
- NCT07011056
- Testing
- Purinostat Mesylate for Injection, Selinexor Tablets
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01546142
- Testing
- Deoxycholic acid injection
- Where
- 35 sites in United States, Canada
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Leukemia, Lymphoma
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)
- Trial name
- NCT03312205
- Testing
- Autologous CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Advanced Solid Tumor
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.
- Trial name
- NCT03272256
- Testing
- IM156
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- ImmunoMet Therapeutics, Inc.
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Multiple Myeloma, Lymphoma
Ixazomib Rollover Study
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
- Conditions
- Multiple Myeloma, Lymphoma, Amyloidosis
- Trial name
- NCT02924272
- Testing
- Ixazomib
- Where
- 26 sites in United States, Belgium and 9 more
- Volunteers
- 32 people
- Sponsor
- Takeda
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer.
- Trial name
- NCT05624554
- Testing
- Nemtabrutinib, Fludarabine, Cyclophosphamide
- Where
- 97 sites in United States, Australia and 19 more
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoblastic Leukemia, Acute, Adult, B Cell ALL
Expanded Access Program for OOS Obe-cel
The purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured from their blood cells but the product is deemed OOS (does not meet…
- Trial name
- NCT06799221
- Testing
- Out-of-specification obecabtagene autoleucel
- Where
- 32 sites in United States
- Sponsor
- Autolus Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.